Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) has shared an update.
WuXi AppTec reported strong financial results for the year ended December 31, 2025, with revenue rising 15.8% year on year to RMB45,456.2 million and gross profit jumping 33.5% to RMB21,379.1 million, lifting gross margin to 47.0%. Net profit attributable to shareholders more than doubled to RMB19,194.9 million, while adjusted non-IFRS net profit rose 41.3% to RMB14,956.5 million, reflecting significantly improved profitability.
Earnings per share also surged, with basic EPS up 107.4% to RMB6.72 and adjusted non-IFRS basic EPS up 42.5% to RMB5.23, underscoring robust earnings growth for investors. The board proposed a final cash dividend of RMB15.7927 per 10 shares, totaling approximately RMB4.71 billion based on current share capital, subject to shareholder approval, signaling confidence in the company’s cash generation and commitment to shareholder returns.
The most recent analyst rating on (HK:2359) stock is a Hold with a HK$124.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a China-based pharmaceutical and biotech services provider listed in Hong Kong, offering contract research, development and manufacturing services to global drug developers. The company operates across the pharmaceutical R&D and manufacturing value chain, with a market focus on supporting international and domestic healthcare customers through integrated, end-to-end solutions.
Average Trading Volume: 4,883,675
Technical Sentiment Signal: Buy
Current Market Cap: HK$303.7B
See more insights into 2359 stock on TipRanks’ Stock Analysis page.